Working Papers, Open Access and Cyber-Infrastructure in Classical Studies

Princeton–Stanford Working Papers in Classics is a web-based series of work-in-progress scripts by members of two leading departments of classics. It introduces the humanities to a new form of scholarly communication and represents a major advance in the free availability of classical-studies scholarship in cyberspace. This article both reviews the initial performance of this open-access experiment and the benefits and challenges of working papers more generally for classical studies. After two years of operation Princeton–Stanford Working Papers in Classics has proven to be a clear success. This series has built up a large international readership and a sizeable body of preprints and performs important scholarly and community-outreach functions. As this performance is largely due to its congruency with the working arrangements of ancient historians and classicists and the global demand for open-access scholarship, the series confirms the viability of this means of scholarly communication and the likelihood of its expansion in our discipline. But modifications are required to increase the benefits this series brings and the amount of scholarship it makes freely available online. Finally departments wishing to replicate its success will have to consider other important developments, such as the increasing availability of postprints, the linking of research funding to open access, and the emergence of new cyber-infrastructure

International forum: Transfusion of apheresis platelets and ABO groups.

Item does not contain fulltex

Red cell transfusion in medicine: future challenges

Item does not contain fulltex

De erytrocyt en transfusie: potentiële neveneffecten en uitdagingen.

Item does not contain fulltex

Auto-immuun-hemolytische anemie: klinische en laboratoriumaspecten.

Item does not contain fulltex

Klinische toepassing van synthetische bewaarvloeistoffen en fotochemische pathogeenreductie bij plaatjesconcentraten bij hemato-oncologische patiënten.

Item does not contain fulltex

Een patiënt met trombocytenrefractaiiteit op basis van complexe antistofproblematiek: transfusie Strategie.

Item does not contain fulltex

Platelet transfusion therapy: from 1973 to 2005.

Item does not contain fulltextPlatelet transfusions are indispensable for supportive care of patients with hematological diseases. We describe the developments in platelet products for transfusion since the 1970s, when, in particular, support for patients with allo-antibodies against human leukocyte antigens was a laborious exercise with a high failure rate. Currently, due to many stepwise innovations, platelet transfusions are of low immunogenicity and sufficiently available, they have a shelf life up to 7 days, and even matched platelets can often be routinely delivered, provided that there is good communication between all partners in the chain. Future improvements can be expected from uniform type and screen approaches for immunized patients and cross-matching by computer. For efficient use of health care resources, blood banks and stem cell donor banks could share their typed donor files

Oorzaken en klinische consequenties van neonatale trombocytopenie bij 237 neonaten in 5 ziekenhuizen in zuidoost Nederland.

Item does not contain fulltex

Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis.

Contains fulltext : 81063.pdf (publisher's version ) (Closed access)OBJECTIVES: To report on 2 cases of metastatic renal cell cancer treated with sunitinib during chronic hemodialysis. METHODS: Two patients who were receiving chronic hemodialysis were treated with escalating doses of sunitinib with close clinical and laboratory surveillance. RESULTS: The treatment toxicities were tolerable even after dose escalation. The first patient had a complete response after 5 treatment cycles and the second patient had stable disease after 13 treatment cycles. CONCLUSIONS: Sunitinib treatment is feasible and effective against metastatic renal cell cancer with the patient receiving chronic hemodialysis. Patients with terminal renal failure can be offered sunitinib treatment with close clinical and laboratory monitoring